Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel

Inclusion Criteria: * 18- 80 years of age * One of the following histologies: * Diffuse large B-cell lymphoma (DLBCL) not otherwise specified, or * Primary mediastinal B-cell lymphoma, or * High grade B-cell lymphoma, or * DLBCL arising from follicular lymphoma * Disease status: * Chemotherapy refractory disease after ≥2 lines of chemotherapy, or * Relapsed with no remission after ≥1 lines of salvage chemotherapy, or * Relapsed following autologous hematopoeitic stem cell transplantation (and failed at least 2 prior lines of therapy including high dose chemotherapy). If salvage therapy is given post auto HCT, the subject must have no complete response, or relapse after the last line of therapy * Performance Status * ECOG performance status 0-2 * Adequate organ function defined as: * Renal function defined as: * eGFR ≥ 30 mL/min/1.73 m\^2 * Liver function defined as: * ALT and AST ≤ 5 times the ULN for age (unless due to disease) * Bilirubin ≤ 2.0 mg/dl with the exception of patients with Gilbert syndrome; may be included if their total bilirubin is ≤ 3.0 x ULN and direct bilirubin ≤ 1.5 x ULN * Hemodynamically stable and LVEF ≥ 40% confirmed by echocardiogram or MUGA * Women of childbearing potential and men with partners of child-bearing potential must agree to use of contraception for the duration of treatment as outlined in axi-cel protocol. * Able to provide written voluntary consent (or LAR consent for adults with diminished capac…